DENVER, Colo. (247marketnews.com) -- Aethlon Medical (NASDAQ:AEMD) is making a dramatic turn from medical-device developer to clinical-stage immunology company, announcing an all-stock merger with privately held North Immunology alongside an oversubscribed $180 million financing.
The deal puts the spotlight squarely on North’s lead asset, NOR-101, a half-life-extended IL-13 × IL-18 bispecific antibody being developed for atopic dermatitis (AD) and potentially other immune-mediated diseases. If completed, the combined company will operate as North Immunology and is expected to trade on the Nasdaq Capital Market under NASDAQ: NRTX. The transaction is targeted for the first quarter of 2027 and remains subject to shareholder, SEC and Nasdaq approvals and other closing conditions.
The capital infusion is the headline within the headline: North says the approximately $180 million financing should fund operations into the second half of 2028. That gives the company a runway to move NOR-101 from preclinical development into the clinic and potentially produce multiple clinical readouts over the next two years.
The timing is notable because the atopic dermatitis market already has established biologic therapies targeting IL-13, including lebrikizumab and tralokinumab, while dupilumab targets IL-4/IL-13 signaling.
“By simultaneously targeting type 2 and non-type 2 inflammatory pathways that drive AD, we believe NOR-101 has the potential to deliver a best-in-disease therapeutic profile,” North Immunology Co-Founder and CSO Mohit Gupta said.
That is an ambitious proposition, but it is still a proposition. NOR-101 has not yet produced clinical efficacy or safety results in humans. The company says its first Phase 1a trial is expected to begin in the first quarter of 2027, with interim pharmacokinetic and safety data anticipated by mid-2027. Phase 1b and Phase 2b studies in atopic dermatitis are planned for 2027, with topline results targeted for 2028.
North CEO Jonathan Barr pointed to a reported approximately 42-day half-life in a non-human primate pharmacokinetic study, calling the preclinical profile encouraging. The eventual test will be whether that profile translates into meaningful human pharmacology, safety and, ultimately, clinical benefit.
The transaction also represents a major change in ownership economics for existing Aethlon shareholders. At closing, pre-merger Aethlon holders are expected to own approximately 4.75% of the combined company, compared with approximately 95.25% for pre-merger North Immunology holders and participating financing investors. Aethlon shareholders are also slated to receive contingent value rights tied to potential future monetization of the legacy Hemopurifier business.
In other words, this is effectively a reset of the investment story. Aethlon's Hemopurifier becomes a potential residual-value asset, while NOR-101 becomes the centerpiece of the new company's growth narrative.
For investors watching the next chapter, the calendar now matters. The first major catalyst is the proposed 2027 Phase 1a start, followed by pharmacokinetic and safety data, then the planned 2027 dose-escalation/early clinical development work and 2028 efficacy readouts.
The story has money, a defined clinical roadmap and a novel mechanism. What it does not have yet is human clinical proof. That distinction is likely to define the next phase of NASDAQ: AEMD and, if the merger closes, NASDAQ: NRTX.
Important Editorial Note: 247 highlights companies approaching significant catalysts and inflection points. This report reflects information available at the time of publication. Since developments can occur rapidly, readers should independently verify current information and review all company filings and disclosures.